Skip to content

Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine

Cohort Study on the Efficacy of Traditional Chinese Medicine Syndrome Differentiation Scheme in Adjuvant Treatment of Severe Pneumonia Based on the Real World

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06613659
Enrollment
1016
Registered
2024-09-26
Start date
2024-09-20
Completion date
2027-10-30
Last updated
2024-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Infections

Keywords

Community-Acquired Infections, Traditional Chinese Medicine, Cohort study

Brief summary

This is a multicenter, prospective cohort study, with syndrome differentiation and treatment of traditional Chinese medicine as the exposure factor. Patients using syndrome differentiation of traditional Chinese medicine combined with conventional treatment of Western medicine are classified as the treatment cohort of Integrated Chinese and Western medicine, and patients using conventional treatment of Western medicine only are classified as the treatment cohort of Western medicine

Detailed description

Severe pneumonia is a severe respiratory disease with high mortality, many complications and poor prognosis. Traditional Chinese medicine has certain curative effect in the adjuvant treatment of severe pneumonia, but there is a lack of systematic TCM syndrome differentiation scheme and its curative effect evaluation in the real medical environment. The cohort study on the efficacy of TCM syndrome differentiation scheme in the adjuvant treatment of severe pneumonia is conducive to providing new evidence for the optimization and evidence-based evaluation of TCM treatment scheme for severe pneumonia. Therefore, this study took severe pneumonia as the research object, standardized use of traditional Chinese medicine diagnosis and treatment scheme as the exposure factor, carried out a multi center prospective cohort study, used the 90 day mortality, 28 day mortality, treatment failure rate, etc., to evaluate the clinical efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of severe pneumonia, and provided evidence for the application and promotion of traditional Chinese medicine in severe pneumonia.

Interventions

Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.

Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.

Sponsors

Henan University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* It met the diagnostic criteria of severe pneumonia; * Age ≥ 18 years old, regardless of gender. * Voluntary treatment. * Sign the informed consent form.

Exclusion criteria

* Pregnant or lactating women; * Patients with mental illness who are unable to cooperate or unwilling to cooperate with follow-up; * Those who are participating in clinical trials of other drugs; * Known allergic to therapeutic drugs.

Design outcomes

Primary

MeasureTime frameDescription
90-day mortalityMortality on the 90th day of treatmentCalculate the proportion of patients who died of the disease on the 90th day of treatment

Secondary

MeasureTime frameDescription
treatment failure rateEarly treatment failure was defined as clinical deterioration within 72 hours of treatment. Late treatment failure between 72 hours and to 28 days.The primary efficacy outcome was the rate of treatment failure, which includes treatment failure that occurred early,late, or at both times.
time to clinical stabilityevery day in the treatment.temperature of 37.2°C orlower, heart rate of 100 beats/min or lower, systolic blood pressure of 90 mm Hg or higher, and arterial oxygen tension of 60 mm Hg or higher when the patient was not receiving supplemental oxygen.
ICU stay timethe 28 days of the treatment phase.length of ICU and hospital stays will be recorded.
hospitalization timethe 28 days of the treatment phaselength of hospital stays will be recorded.
28-day mortalityCalculate the proportion of patients who died of the disease on the 28th day after discharge
SOFA scoreThe sofa scores of the first, seventh, fourteenth, twenty-first and twenty-eight days of admission and the first, second and third months after discharge were counted.Sequential Organ Failure Assessment.It is a scoring system for evaluating and monitoring the organ function of critically ill patients.The minimum score is 0 and the maximum is 24. The higher the score, the worse the result.
Quality of lifeThe scores of the first, seventh, fourteenth, twenty-first and twenty-eight days of admission and the first, second and third months after discharge were countedScore according to the quality of life table,the minimum score is 12 points, and the maximum score is 60 points. The higher the score, the worse the result.
TCM syndrome scoreThe TCM syndrome scores of the first, seventh, fourteenth, twenty-first and twenty-eight days and the first, second and third months after discharge were countedTraditional Chinese Medicine Syndrome Points.Including cough, expectoration, dyspnea, chest pain, anorexia and fatigue, each item is rated as 1-5 points from mild to severe.The minimum score is 6 points and the maximum score is 30 points. The higher the score, the worse the result.
90 day readmission rateThe proportion of rehospitalization due to exacerbation within 90 days after discharge was recordedThe proportion of rehospitalization due to exacerbation within 90 days after discharge was recorded
Mechanical ventilation timethe 28 days of the treatment phaseTime of invasive mechanical ventilation

Countries

China

Contacts

Primary ContactHaifeng Wang, doctor
wangh_f@126.com86-371-66248624
Backup Contactjiangsheng Li, doctor
li_js8@163.com86-371-66248624

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026